Background: There are several possible malaria prevention strategies for travellers. In Switzerland, chemoprophylaxis (CP) is recommended for persons visiting areas highly endemic for malaria and stand-by emergency treatment (SBET) for areas with moderate to low risk. Objective: To describe the type of malaria prevention prescribed to travel clinic attendees with a specific focus on changes over time following adaptation of recommendations. Methods: All pre-travel first consultation data recorded between November 2002 and December 2012 were included. Country-specific malaria preventive recommendations provided and medicines prescribed over time were analysed. Results: In total, 64 858 client-trips were recorded. 91% of travellers planned to visit a malaria endemic country. Among those clients, 42% were prescribed an antimalarial medicine as CP only, 36% as SBET only, and 3% both. Between 2002 and 2012, there was a 16% drop of CP prescription (P < 0.001) and a 21% increase of SBET prescription (P < 0.001). Among travellers receiving CP, the proportion of those prescribed mefloquine dropped from 82% in 2002 to 46% in 2012 while those prescribed atovaquone-proguanil (AP) increased from 7% to 39%. For those prescribed SBET, the proportion dropped from 46% to 30% for AP and increased from 2% to 61% for artemetherlumefantrine. CP prescription for travellers to India fell from 62% to 5% and SBET prescription increased from 40% to 88% after the change of recommendation from CP to SBET in 2005 for this country. Comparatively, CP prescription for travellers to Senegal, for which no change of recommendation occurred, remained relatively stable between 88% in 2002 and 89% in 2012. Conclusion: This study shows the considerable decline of antimalarial prescription for chemoprophylaxis that occurred over the 10-year period in favour of SBET.
Background
Malaria is one of main tropical causes of fever in returning travellers, particularly from sub-Saharan Africa. 1 In Europe, 99% of reported cases are imported, and >80% are from Africa. 2 In the 80's, the incidence of malaria in European travellers taking no chemoprophylaxis or not taking into account its use was 15.2/1000/month and 1.7/1000/month in East Africa, and 24.2/1000/month and 3.8/1000/month in West Africa. [3] [4] [5] Malaria has been declining for the last 15 years in some parts of the world. Global estimates of malaria case incidence rates fell by 30% between 2000 and 2013, while estimated mortality rates fell by 47%. 6 In sub-Saharan Africa, the prevalence of Plasmodium falciparum infection decreased by 50% over the last decade, while its incidence fell by 40%. 7 Consequently, Switzerland and several other European countries have decided to switch from malaria chemoprophylaxis (CP) to stand-by emergency treatment (SBET) in case of fever for travellers visiting areas with moderate to low-risk of malaria transmission. The rationale is that when the incidence of serious adverse events due to the CP is superior to the risk of severe malaria, then SBET should be favoured. CP remains the favoured option for areas with high endemicity. This new preventive strategy is largely debated and many countries do not endorse this recommendation.
Our study objective was to determine the type of malaria prevention recommended to travellers by health professionals working in a large travel clinic in Switzerland, with a special focus on dynamics of CP and SBET over time (10 year-period) for different geographic zones visited, according to changes in national recommendations.
Materials and Methods

Data Collection
The study was conducted at the travel clinic, Department of Ambulatory Care and Community medicine, University of Lausanne, Switzerland from November 2002 to December 2012. Data were prospectively collected from electronic medical files of all consecutive attendees of pre-travel consultations using a custom-made program (DIAMM/G version 6.5.5, 1985 6.5.5, -2002 .
The outcomes of interest were: (i) proportion of travellers prescribed CP or SBET overall and over time; (ii) type of medication used for CP and SBET overall and over time; (iii) specific preventive measures among special groups.
In addition, we analysed country-specific malaria preventive recommendations provided and medication prescribed over time for several destinations, two of them without change of malaria recommendations during the period of observation (CP for Senegal, SBET for Thailand), and one with a change (CP to SBET for India).
The reference standard for the changes of national malaria recommendations was the document of the Federal Office of Public Health (FOPH) developed and updated biyearly by the Swiss Working Group for Health Advice to Travellers that includes experts from Switzerland, Germany, UK, Austria, The Netherlands and Italy. 8 
Data Processing and Analysis
Data processing was performed using Microsoft Office Excel 2007 and the statistical analysis using the software Epi Info (CDC version 7.0). Each record on the database represented one person-travel. Thus, a person was counted once for each travel, i.e. once even if he/ she came several times for pre-travel advice. We used inferential statistics for the annual trend of antimalarial prescription (i.e. Chi Square X 2 test (Extended Mantel-Haenszel)) using StatCalc Epi Info7.
Results
From November 2002 to December 2012, 65 046 client-trips were recorded at the travel clinic. Details of demographic and travel characteristics of this population have been described elsewhere. 9 Median age was 32 years old. 18 .9% (11 152/59 003) of those going to an endemic country did not get any medication (data unknown for 0.6% (338/59 003)). Most of them should have received antimalarials, though some might have gone to non-endemic areas within an endemic country (a within-country destination analysis was not performed). Figure 1 shows the percentage of travellers per endemic country who had not been prescribed any antimalarial. 
Overall Analyses of Malaria Preventive Measures in the Study Population
Stand-by Emergency Treatment
Over the 10-year period of the study, 37. 
Antimalarial Prescription for Special Groups
36.4% (23 668/65 046) of clients belonged to special groups of travellers, namely VFRs (17.6%, 11 474/65 011), long-term travellers (9.1%, 5 938/65 045), seniors (9.0%, 5 860/65 018), pregnant women (0.9%, 210/23 569), breastfeeding mothers (1.0%, 99/10 052) and infants (0.1%, 87/65 018). All of these groups but infants and breastfeeding mothers are considered more at risk of severe malaria. Table 1 describes the antimalarial medication prescribed over time for these special groups compared with that prescribed to all other travellers.
CP was prescribed more often for VFRs than for others [57.9% (6 641/11 474)] vs 37.1% (15 339/41 378), P < 0.001] and SBET for long-term travellers than for others [56% (3 326/ Table 2 and Figure 4 detail the type of antimalarial prescribed for CP in special groups of travellers. In all these special groups, mefloquine was the most commonly prescribed medication in those who received CP, e.g. in 66% (4 383/6 641) of VFRs and 59.6% (1 025/1 721) of long-term travellers, except for seniors who got more often atovaquone/proguanil [35.9% (857/2 387)]. Table 3 details the type of antimalarial prescribed as SBET in the same special groups of travellers. Atovaquone/proguanil was the most common prescribed medication in those who received SBET, e.g. in 42.2% (1 111/2 632) of VFRs and 47.9% (1 593/3 326) of long-term travellers.
Country-Specific Analysis of Malaria Preventive Measures Over Time
Among 210 destinations, three countries were selected to assess the type of malaria prevention prescribed according to the change or no change in malaria recommendations for each destination over the period of observation.
Africa
Senegal There was no change in recommendations over time. CP was always the option proposed for Senegal for example, due to high level of malaria transmission in the country up to 2012 and predominance of Plasmodium falciparum.
Over the period of observation, 89.4% (2 789/3 121) of travellers to Senegal received CP and 3.1% (96/3 121) SBET. The proportion of travellers prescribed CP or SBET over time is illustrated in Figure 5a . CP prescription was stable for the first 2 years around 89% and then decreased slightly onwards from 95. 
Discussion
To our knowledge, this is the largest and longest study ever published on malaria prevention practices from one travel clinic. It is based on the collection of routine files of attendees over a period of 10 years. The main interest of such a cohort is the analysis of the changes that occurred over time as a result of the adaptation of malaria recommendations to the decline of malaria and to the availability of new drugs. About four out of five travellers to endemic countries were prescribed CP or SBET or both together. This means that one out of five travellers were left without any prevention, outside potential exposure prophylaxis, and hence potentially at risk of acquiring severe disease. In fact, most of these travellers were going to countries where the endemicity is quite heterogeneous, and they may thus have been advised not to take any antimalarial drug, either as CP or SBET, because the risk was minimal in the specific zone visited. Few of those not taking any medication were actually going to highly endemic areas (see Figure 1) ; these might represent the true CP or SBET refusers.
Compared with 10 years earlier, there was a 16% drop of CP prescription, which was given to only 38% of travellers in 2012. On the reverse, there was a 21% increase of SBET prescription, which was given to 40% in 2012. At the end of the observation period, there were thus at least as many travellers that were prescribed SBET as CP. The gradual switch of malaria prevention policy from CP to SBET in several countries during the observation period was therefore reflected in the respective proportions of travellers who got CP or SBET. This tendency does not only reflect changes in malaria recommendations, but also, at least in Europe, change in consumer preferences because of concern about potential adverse drug reactions, as shown in a study conducted in the travel clinic in Lausanne. 10 The dynamic of malaria prevention strategies that we observed in our travel clinic is thus a mixture of change in malaria recommendations over time but also a change in travellers risk perception, probably better awareness, and eventually more responsive attitude towards their own health. It also reflects a tendency for more decision-sharing between the health care provider and the client nowadays. 11, 12 CP and SBET were prescribed together mainly for long-term travellers and backpackers travelling to several destinations. Travellers were supposed to use SBET either in some of the destinations where the risk was low, or as backup therapy to cover CP failure. 13 As far as antimalarial regimens are concerned, the prescription of mefloquine decreased considerably over the 10-year period while that of atovaquone-proguanil gradually increased. At the same time doxycycline prescription was rather stable with some yearly fluctuations. This dynamic is certainly the consequence of the bad press around mefloquine, even before the release of the US Food and Drug Administration warning in 2013, and that of the European Medicines Agency that recommended strengthening warnings and updates of the product information. 14, 15 It also results from the marketing strategy of GlaxoSmithKline to promote atovaquone-proguanil for CP. Again, travellers preference may have played a role, although a study in the waiting room of the travel clinic in Lausanne conducted in 2006 showed that 45% would still be choosing mefloquine, 21% atovaquone-proguanil, 18% doxycycline, 5% no prophylaxis, and 11% did not know. About half of the travellers chose then mefloquine and the main reasons for their choice were first the cost, and then a previous good experience with this medication. 16 However, the costs determine much more the choice of the antimalarial type for CP rather than the choice between CP and SBET. In a recently published study, we investigated more specifically the determinant for choosing CP or SBET or exposure measures only and found that actually the most important reasons for the traveller to choose CP were for security reasons (42%), better preventive action (29%), higher efficacy (15%) and easiness (15%), and the reasons for choosing stand-by treatment or bite prevention only were less medication consumed (29%), less adverse drug reactions (23%) and lower price (9%). 10 Cost is thus by far not the major determinant.
For SBET, atovaquone-proguanil and artemether-lumefantrine were the main type of medicine used for travellers. Their prescription over time showed some fluctuations, with an upsurge when the combinations were marketed for this indication. Mefloquine was definitely abandoned for SBET when other better tolerated drugs appeared on the market. The choice between atovaquoneproguanil or artemether-lumefantrine is always discussed in our travel clinic between the health care provider and the client. If no formal contra-indication is identified, the choice is usually left to the client after information on the advantages and disadvantages of each combination. The higher proportion of travellers getting artemether-lumefantrine at the end of the period reflects a preference from the health staff in the travel clinic to propose atovaquone-proguanil for CP and artemether-lumefantrine for SBET in order to avoid confusion for the traveller. Also, the excellent tolerance and effectiveness of the latter in a formal study of imported malaria 17 and in several millions of recipients in Africa are advantages over atovaquone-proguanil for a medicine that is given to an immunologically naïve traveller. More than one third of the travel clinic attendees belonged to special groups of travellers. This confirms that travel clinic attendees represent a biased population of travellers, usually more at risk of acquiring malaria infection. VFRs composed about half of all special groups; they were more often prescribed CP than the usual travellers. This higher rate reflects the VFRs destinations which are most often sub-Saharan Africa where CP is the recommendation. There were a higher proportion of mefloquine users in this group, probably because VFRs are more often travelling with the whole family, which allows to having a CP that is not too expensive. Pregnant women and small children were also most often prescribed mefloquine, which reflects the known good safety profile in these groups. 18 On the reverse, long-term travellers were more often prescribed SBET when compared with the usual travellers. This finding results from the fact that this group is known to have poor adherence to chemoprophylaxis [19] [20] [21] [22] and usually prefers SBET that is less expensive and allows to being relatively independent when travelling to more remote places. Also they usually visit several countries that have different malaria recommendation strategies, which would require to constantly being starting and stopping CP. Nowadays, we propose to long-term travellers to also carry Rapid Diagnostic Tests (RDTs) in addition to the SBET, which allows them to knowing whether they should take the antimalarial drug or not. Following studies that did not show much value of this strategy in the past, 23 we conducted a feasibility study to assess travellers' behaviour, satisfaction and incidence of malaria among users of this new diagnostic tool. 10 These tests are only provided with standard detailed oral and written information on appropriate procedures and attitudes and after a run of the process with real pricking on themselves at the travel clinic. This study highlighting the usefulness of adding RDTs to SBET for special groups showed that indeed the RDTs allowed to diagnose four cases of malaria among 500 travellers that took RDTs with SBET (Berthod and D'Acremont, personal communication, 2015). The cost of adding RDTs is fixed so as to be affordable for all clients (including necessary procedures, reagents etc.). The comparison between countries for which no major change in recommendation occurred, such as Senegal, and a country for which a switch from CP to SBET took place during the study period, such as India, highlights the impact that national guidelines do have on practices. Adapting recommendations to the changing epidemiology, or even micro-epidemiology, appears to be feasible. Even if refined intra-country guidelines can be proposed, as it is the case in Kenya for example, such recommendations are not always easy to implement. The avenue is maybe to have more flexible prevention strategies that take into account client preferred option. 10 Addition of Rapid Diagnostic Tests to SBET could even be an additional tool in the armamentarium.
Limitations
Despite of being the largest and longest first study ever published on malaria prevention strategies, the outcomes in terms of drugs prescription over time following the national changes in recommendations are still a reflection of practices in only one Swiss travel clinic. A comparison with the other Swiss travel clinics might be of interest with regard to standardized health professional practices throughout the country. Also, in spite of the efforts of the clinic professionals to provide appropriate advice for the particular traveller while complying with national policies, and take into account the client's choice in decision-making, the present study does not provide any information on travellers' adherence during their trip, which is an important component of the assessment of practices.
Conclusion
Over a 10-year period, there was a drop of CP prescription in favour of SBET which was prescribed to >40% of all travellers visiting malaria endemic areas in 2012. Changes in market availability of antimalarials were reflected in the type of medicine prescribed.
A detailed surveillance of attack rates of imported malaria in travellers according to the destination is indispensable to appropriately assess the changes of recommendations. Ideally, recording all malaria deaths while abroad, type of malaria prevention measures as well as level of adherence, health services utilization including hospitalizations would help to better evaluate their appropriateness for a particular setting. At least, this information should be recorded for imported malaria cases. The use of SBET and the potential of new generations of RDT to assist the traveller in decision-making should also be investigated.
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